Tuesday , 23 January 2018
Masonic Cancer Center researchers identify genetic variation behind acute myeloid leukemia treatment success

Masonic Cancer Center researchers identify genetic variation behind acute myeloid leukemia treatment success

Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered to identify genetic variations that may help signal which acute myeloid leukemia (AML) patients will benefit or not benefit from one of the newest antileukemic agents. Their study is published today in Clinical Cancer Research.

CANCER CENTER

About the Medical School

The University of Minnesota Medical School, with its two campuses in the Twin Cities and Duluth, is a leading educator of the next generation of physicians. Our graduates and the school’s 3,800 faculty physicians and scientists advance patient care, discover biomedical research breakthroughs with more than $180 million in sponsored research annually, and enhance health through world-class patient care for the state of Minnesota and beyond. Visit med.umn.edu to learn more.

About the Masonic Cancer Center

Masonic Cancer Center, University of Minnesota is part of the University’s Academic Health Center. It is designated by the National Cancer Institute as a Comprehensive Cancer Center. For more information about the Masonic Cancer Center, visit cancer.umn.edu or call 612-624-2620.

A Legacy of Masonic Support

In April 2008, Minnesota Masonic Charities presented the University of Minnesota with an extraordinary gift of $65 million—the largest gift ever made to the University—to seek the cure for cancer. In recognition of the gift, the name of the University’s cancer center was changed to Masonic Cancer Center, University of Minnesota.

(source:  http://presszoom.com/story_180604.html)